MVZ für Hämatologie u. Onkologie PD Dr. med. Jan Schröder / Dr. med. Katharina Sieg
- Address
- lock Available on a paid plan
MVZ für Hämatologie u. Onkologie PD Dr. med. Jan Schröder / Dr. med. Katharina Sieg
This specialized medical center for hematology and oncology focuses on advanced treatment approaches for cancer patients, with particular expertise in precision medicine and targeted therapies. Under the leadership of PD Dr. med. Jan Schröder and Dr. med. Katharina Sieg, the center participates in cutting-edge clinical research to improve outcomes for patients with various malignancies.
- Breast cancer with germline BRCA mutations
- Adjuvant targeted therapy with PARP inhibitors
- HER2-negative high-risk primary breast cancer management
The center demonstrates commitment to personalized cancer care by investigating olaparib as adjuvant treatment in patients with germline BRCA mutated breast cancer. Their research focuses on improving invasive disease-free survival (IDFS) through innovative therapeutic strategies that address the specific genetic profiles of tumors, representing the forefront of precision oncology in breast cancer treatment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ für Hämatologie u. Onkologie PD Dr. med. Jan Schröder / Dr. med. Katharina Sieg
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of BrECADD Versus Escalated BEACOPP in First-Line Treatment of Advanced Hodgkin Lymphoma: A Randomized Controlled Trial | University Of Cologne | Phase III | Not Recruiting | Jul 2016 | Dec 2024 |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide Monohydrate | 2 | Unknown | 2016-07-15 | 2018-06-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.